NCT01489969View on ClinicalTrials.gov

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

January 31, 2013

Conditions
Primary Insomnia
Interventions
DRUG

Neu-P11

1 tablet daily 1-2 before bed time for 28 days of double blind treatment

Trial Locations (9)

10119

Clinilabs, Inc., New York

20815

Center for Sleep and Wake Disorders, Chevy Chase

30342

Sleep Disorders Centers of Georgia, Atlanta

33009

MD Clinical, Hallandale

33143

Miami research Associates, South Miami

41017

Community Research and Sleep Management, Crestview Hills

60634

Chicago Research Center, Chicago

66212

Vince & Associates Clinical Research, Overland Park

92103

Pacific Research Network, San Diego

Sponsors
All Listed Sponsors
lead

Neurim Pharmaceuticals Ltd.

INDUSTRY

NCT01489969 - Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients | Biotech Hunter | Biotech Hunter